Diker Management LLC Invests $419,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Diker Management LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 5,222 shares of the medical equipment provider's stock, valued at approximately $419,000. Lantheus accounts for 0.4% of Diker Management LLC's holdings, making the stock its 26th biggest position.

Other hedge funds have also recently bought and sold shares of the company. Daiwa Securities Group Inc. acquired a new stake in Lantheus during the 1st quarter valued at approximately $1,269,000. Nordea Investment Management AB grew its stake in Lantheus by 42.6% during the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider's stock valued at $2,932,000 after purchasing an additional 14,147 shares in the last quarter. Hancock Whitney Corp grew its stake in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lantheus in the 2nd quarter worth approximately $290,000. Finally, Pitcairn Co. increased its holdings in shares of Lantheus by 117.0% in the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider's stock valued at $521,000 after acquiring an additional 4,509 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

LNTH traded down $3.52 during trading on Thursday, reaching $104.43. 1,033,274 shares of the company were exchanged, compared to its average volume of 1,014,065. The stock has a market cap of $7.24 billion, a P/E ratio of 15.94 and a beta of 0.50. The firm has a 50 day moving average of $104.64 and a 200 day moving average of $85.38. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same quarter in the previous year, the company earned $1.40 earnings per share. Lantheus's quarterly revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. JMP Securities lowered their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Finally, Leerink Partners boosted their price target on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

Insiders Place Their Bets

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the business's stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the transaction, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gary J. Pruden sold 12,530 shares of the company's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.